Song Juexian, Lyu Yi, Wang Miaomiao, Zhang Jing, Gao Li, Tong Xiaolin
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Department of Medical Affairs, Techpool Biopharma Co., Ltd., Guangzhou, China.
Front Physiol. 2018 Feb 12;9:84. doi: 10.3389/fphys.2018.00084. eCollection 2018.
To evaluate the clinical efficacy of Human Urinary Kallidinogenase (HUK) and Maixuekang capsule in the treatment of acute ischemic stroke (AIS) patients. In this study, from January 2016 to July 2016, 60 patients with acute ischemic stroke were enrolled and 56 patients with complete information of whom 21 patients received HUK+ basic treatment (HUK group), 16 patients received HUK+ Maixuekang capsule + basic treatment (HUK+ Maixuekang group), 19 patients received basic treatment (control group). 0.15 PNA unit of HUK injection plus 100 ml saline in intravenous infusion was performed in the HUK group and HUK+ Maixuekang group, with once a day for 14 consecutive days. 0.75 g Maixuekang capsules were taken in HUK+ Maixuekang group, with three times a day for 14 consecutive days. The National Institutes of Health Stroke Scale (NIHSS) scores in three groups were analyzed 7 days after treatment. The modified Rankin Scale (mRS) scores in three groups were analyzed 12 month after the treatment. No difference was found in the NIHSS scores, age, gender, and comorbidities between three groups before treatment ( > 0.05). Seven days after treatment, the NIHSS scores in the HUK group and HUK+ Maixuekang group were significantly decreased than before (p = 0.001, p < 0.001), and lower than that in the control group (p = 0.032; p < 0.001). Twelve months after treatment, good functional outcome rate (12 month mRS score ≤ 2) in the HUK group and HUK+ Maixuekang group was significantly higher than that in the control group (p = 0.049, p = 0.032). The treatment of HUK or HUK combined with Maixuekang capsule can effectively improve the neurological function and promote long-term recovery for AIS patients.
评估人尿激肽原酶（HUK）和脉血康胶囊治疗急性缺血性脑卒中（AIS）患者的临床疗效。本研究纳入2016年1月至2016年7月的60例急性缺血性脑卒中患者，其中56例资料完整，21例接受HUK+基础治疗（HUK组），16例接受HUK+脉血康胶囊+基础治疗（HUK+脉血康组），19例接受基础治疗（对照组）。HUK组和HUK+脉血康组采用0.15PNA单位HUK注射液加100ml生理盐水静脉滴注，每日1次，连续14天。HUK+脉血康组口服脉血康胶囊0.75g，每日3次，连续14天。治疗7天后分析三组的美国国立卫生研究院卒中量表（NIHSS）评分。治疗12个月后分析三组的改良Rankin量表（mRS）评分。治疗前三组的NIHSS评分、年龄、性别和合并症差异无统计学意义（>0.05）。治疗7天后，HUK组和HUK+脉血康组的NIHSS评分较治疗前显著降低（p=0.001，p<0.001），且低于对照组（p=0.032；p<0.001）。治疗12个月后，HUK组和HUK+脉血康组的良好功能预后率（12个月mRS评分≤2）显著高于对照组（p=0.049，p=0.032）。HUK或HUK联合脉血康胶囊治疗可有效改善AIS患者的神经功能，促进其长期恢复。
